28 results about "Hippuric acid" patented technology

There is provided a method for diagnosing a subject with early onset muscle atrophy, said method comprising: obtaining a biosample from the subject; and assaying the biosample for one or more biomarkers, said one more biomarkers are taurine, proline, citrulline, trigonelline, thymidine, ornithine, glutamate, L-pyroglutamic acid, creatinine, adenine, nicotinamide, 2-methylhippuric acid, maltol, L-arginine, hypotaurine, L-glutamine, homogentisic acid, methylhistidine, oxoglutaric acid, xanthine, L-carnitine, succinate, or a combination thereof; and identifying the subject with early onset muscle atrophy on the basis of a deviation in the one or more of said one more biomarkers.

The invention discloses an endogenous small molecule metabolite for treating obesity and related metabolic diseases thereof, and belongs to the field of biological medicine. Specifically, the invention relates to application of hippuric acid in preparation of anti-obesity drugs. The invention discloses a technical scheme for treating obesity and related metabolic disorders by hippuric acid, and overcomes the defects of single curative effect, larger side effect or unclear action mechanism and the like in the prior art through the advantages of targeted improvement of liver fatty degeneration, improvement of insulin sensitivity, higher potential safety, provision of a new treatment strategy and the like. The method has remarkable technical progress and clinical application value.

The invention relates to the technical field of marine microorganisms, in particular to application of combined lactobacillus salivarius in preparation of products for improving metabolism of alcohol and uric acid, the combined lactobacillus salivarius NHNK-603 is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 2024416. Experiments show; the NHNK-603 has the effects of inhibiting the growth of klebsiella pneumoniae, inhibiting the production of alcohol, agglutinating the klebsiella pneumoniae, inhibiting the virulence gene of the klebsiella pneumoniae, promoting alcohol metabolism, reducing alcohol damage, tolerating alcohol, degrading uric acid, inhibiting the activity of xanthine oxidase, promoting uric acid excretion, promoting the proliferation of Alistipes indinctus and synthesizing hippuric acid; the thallus biofilm increases the function of colonization on mucoprotein and intestinal epithelial cells, and can be applied to preparation of products for improving metabolism of alcohol and uric acid.

A quinazoline derivative (represented by the formula (I)) salt's crystal form, a preparation method and application are provided; specifically, the hydrochloride crystal form A, B, C, D, F, H, I, Sulphate crystal form A, Maleate crystal form A, Succinate crystal form A, Adipate crystal form A, Glycolate crystal form A, Malate crystal form A, Fumarate Salt crystal form A, besylate crystal form A, B, C, benzoate crystal form A, hippurate crystal form A and oxalate crystal form A of the quinazoline derivative represented by formula (I). The salt crystal form provided by the present invention has good stability, which can be used in the treatment of non-small cell lung cancer brain metastasis, meningeal metastasis, primary brain cancer or glioma, etc., and has good bioavailability, which is of great significance for further research on the efficacy of such solid drugs.

The invention provides a blood marker for distinguishing lung cancer and non-lung cancer diseases and application of the blood marker, and belongs to the technical field of biomarkers. The blood marker for distinguishing lung cancer and non-lung cancer diseases comprises at least five metabolites as follows: phosphatidylethanolamine (36: 4), lysophosphatidylcholine 18: 1e, phosphatidylethanolamine 38: 7e, sphingomyelin d38: 5, dodecanedioic acid, N-acetylputrescine, L-glutamyl-L-glutamine, hippuric acid, trans-cyclohexane-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3-triazole-1, 3, 4- The compound is prepared from 1, 2-dicarboxylic acid, glycochenodeoxycholic acid, allantoic acid, L-valine, methyleucine and 4-guanidinobutyric acid. A diagnosis model is constructed based on the blood marker, and the area under curve (AUC) is greater than 0.77, which indicates that the diagnosis result is accurate and reliable. The invention provides an effective marker for diagnosis of lung cancer and differential diagnosis of lung cancer and non-lung cancer diseases, greatly simplifies experimental operation, and has important clinical diagnosis significance.

The present invention provides a pharmaceutical composition comprising a radiolabeled complex comprising a radionuclide and a targeting moiety linked to a chelating moiety, and a stabilizer against radiolytic degradation of a radiolabeled complex comprising para-aminohippuric acid or a pharmaceutically acceptable salt or carboxylic derivative thereof. The pharmaceutical composition of the present invention is characterized by high stability of its radiolabeled complex against radiolytic degradation. The present invention also provides a method for preparing such a pharmaceutical composition, and use of para-aminohippuric acid or a pharmaceutically acceptable salt or carboxylic derivative thereof for the stabilization of the radiolabeled complex of such a pharmaceutical composition.

At least the presence of a starting material is detected by measuring glycine formed as a by-product along with a main product through a chemical reaction involving hippuric acid and / or methylhippuric acid as the starting material and catalyzed by a hydrolase. The hydrolase is an aminoacylase having an amino acid sequence of SEQ ID NO: 1 or a protein having the amino acid sequence of SEQ ID NO: 1 in which one or more amino acids are deleted, replaced, or added and having activity for hydrolysis of the hippuric acid and the methylhippuric acid.

The application provides a molecular imprinting electrochemical sensor for hippuric acid detection, a preparation method and a segmented response technology, and belongs to the technical field of electrochemical sensors.The molecular imprinting electrochemical sensor for detecting hippuric acid is prepared by an electrochemical polymerization method based on a functional monomer aniline and o-phenylenediamine and taking hippuric acid as a template molecule.The sensor combines the advantages of molecular imprinting technology and electrochemical technology, has excellent sensitivity, fast response time and specific recognition ability, has good signal response for hippuric acid detection under different concentrations, generates a good electric signal in a 0-100nM hippuric acid solution, and forms a better linear relationship between the electric signal and the concentration in a hippuric acid solution with a concentration of more than 100nM, so that the signal response and detection range of the molecular imprinting electrochemical sensor under high concentration are widened, and the molecular imprinting electrochemical sensor is suitable for hippuric acid detection under a wide range.

The invention discloses extraction and application of uric acid reducing active components of gynura procumbens, and relates to the technical field of traditional Chinese medicine efficacy material basis and action mechanism research, and the method comprises the following steps: extract preparation, intestinal flora regulation effect verification, flora intermediary effect verification through coprophilous fungus transplantation, and action mechanism verification. In the invention, in the aspect of mechanism, a flora-host co-metabolism theory is introduced, and a new idea that the extract can indirectly influence uric acid metabolism through intestinal local regulation flora is provided; in the aspect of flora regulation, the extract can specifically improve the abundance of A. indinctus by about 2 times, the hippuric acid generation amount is accurately promoted to be increased by 30.3%, and the uncertainty of conventional intervention is avoided; a coprophilous fungus transplantation experiment shows that the uric acid reducing effect of flora transplantation is obviously superior to that of a pure component effect, and a brand new uric acid reducing mechanism is disclosed; in an application scene, the traditional uric acid reducing way is bypassed, the intestinal ABCG2 pathway is activated, and a new hope is brought to a drug-resistant patient.

Provided are a salt and / or a crystal form of a compound degrading BTK and preparation and application thereof. The pharmaceutically acceptable salt and crystal form of the compound as shown in formula (I), wherein the pharmaceutically acceptable salt is selected from a maleate salt, a fumarate salt, a hydrogen halide salt (preferably a hydrobromide salt and a hydrochloride salt), a sulfate salt, a phosphate salt, an L-tartrate salt, a citrate salt, an L-malate salt, a hippurate salt, a D-glucuronate salt, a glycolate salt, a mucate salt, a succinate salt, a lactate salt, an orotate salt, a pamoate salt, a glycine salt, an alanine salt, an arginine salt, a cinnamate salt, a benzoate salt, a benzene sulfonate salt, a p-toluene sulfonate salt, an acetate salt, a propionate salt, a valerate salt, a triphenylacetic acid salt, an L-proline salt, a ferulic acid salt, a 2-hydroxyethanesulfonate salt, a mandelate salt, a nitrate salt, a methanesulfonate salt, a malonate salt, a gentisate salt, a salicylate salt, an oxalate salt or a glutarate salt:

The invention discloses application of hippuric acid in activation of brown adipose tissue heat production and prevention and treatment of obesity, and the application is realized by activating brown adipose tissue heat production, specifically, expression of uncoupling protein 1 in brown adipose tissue is up-regulated, heat production capacity under cold stimulation conditions is enhanced, weight gain and abnormal glucose and lipid metabolism are improved, and the purpose of preventing and treating obesity is achieved. The hippuric acid is preferably derived from walnut oil or metabolites thereof, and has a good application prospect.

The present application discloses para-aminohippuric acid (PAhI) or a pharmaceutically acceptable salt or carboxylic acid derivative thereof for use in methods for reducing the nephrotoxic side effects of radiolabeled and non-radiolabeled therapeutic and diagnostic compounds in a subject. Also disclosed are pharmaceutical compositions comprising a radiolabeled and / or non-radiolabeled pharmaceutical compound and para-aminohippuric acid (PAH) or a pharmaceutically acceptable salt or carboxylic acid derivative thereof and a pharmaceutically acceptable excipient, diluent, carrier, or combination thereof. Another subject of the present application is a method for reducing the nephrotoxic side effects of radiolabeled and non-radiolabeled therapeutic and diagnostic compounds in a subject, comprising administering to the subject para-aminohippuric acid (PAH) or a pharmaceutically acceptable salt or carboxylic acid derivative thereof in combination with a radiolabeled or non-radiolabeled therapeutic or diagnostic compound.

Provided are a free base or pharmaceutically acceptable salt of a pyrazoloquinazoline compound of formula (I), which can be used as a PLK1 inhibitor, optionally in a crystalline form, and a solvate or hydrate thereof, wherein the pharmaceutically acceptable salt comprises a hydrochloride, sulfate, phosphate, maleate, fumarate, L-tartrate, citrate, L-aspartate, hippurate, L-glutamate, L-malate, adipate, glutarate, p-toluenesulfonate, and methanesulfonate of the pyrazoloquinazoline compound of formula (I), and also provided is a pharmaceutical composition comprising same, and a use thereof in the treatment of diseases and conditions caused by dysregulated activity of PLK1 and / or diseases and conditions related to PLK1, such as cancer.

Disclosed herein are methods for promoting healthy neural development in an unborn baby, which include administering to a maternal subject gestating the unborn baby a composition or a bacterial composition. Compositions can include trimethylamine N-oxide (TMAO), 5-aminovalerate (5-AV), imidazole propionate (IP), hippurate (HIP), or a combination thereof, and the bacterial compositions can include bacteria of the order Clostridiales. Also disclosed are methods for conditioning a female subject for bringing about offspring with healthy neural development. Additionally disclosed are methods for reducing adverse effects of antibiotic treatment on an unborn baby in a pregnant subject. Also disclosed are methods for selecting a female subject for conditioning to foster healthy neural development in offspring.

The application discloses application of hippuric acid in preparation of a medicine for preventing and / or treating depression, and belongs to the technical field of biological medicine. The hippuric acid or pharmaceutically acceptable salt thereof has significant and multi-target antidepressant pharmacological activity through chronic mild stress depression animal model experiment. Specifically, in terms of improving core depressive symptoms, the sugar water preference experiment result shows that the hippuric acid can effectively reverse CUMS-induced hedonic deficiency of mice, and significantly improves the sucrose preference rate, and the forced swimming experiment proves that the hippuric acid can significantly shorten the immobility time of mice and relieve behavioral despair; in terms of improving anxiety-like behavior, the mine field experiment data show that after the hippuric acid intervention, the number of times of entering the central area, the residence time and the total activity distance of the depressive model mice are all significantly increased, which indicates that the hippuric acid can effectively improve the spontaneous activity reduction caused by chronic stress.

The application provides an anisaldehyde hippuric acid molecular top and a preparation method and application thereof, and belongs to the technical field of detection of gibberellic acid liquid preparation. The anisaldehyde hippuric acid molecular top has a unique configuration of a rigid aromatic ring rotor and an amide bond flexible support shaft, can convert micro-viscosity changes into visual light signal output, and releases light signal intensity that regularly increases with the increase of micro-viscosity, so that the dilution degree of the gibberellic acid liquid preparation can be observed in real time and accurately controlled. The sensitive coefficient of the MBABG to viscosity is high (x=0.65), the conjugated system formed by the amide bond and the aromatic ring in the molecular structure of the MBABG gives the MBABG excellent chemical stability, the MBABG can resist the complex environment of multiple components such as thickening agents, surfactants and pH regulators in the gibberellic acid liquid preparation, and can exist stably for a long time.

The invention provides application of a complex microbial inoculant FGXOS in production of hippuric acid and improvement or treatment of hyperuricemia, and belongs to the technical field of microorganisms. The invention provides application of a complex microbial inoculant FGXOS composed of lactobacillus gasseri LG020, lactobacillus fermentum LF028 and lactobacillus rhamnosus GS014 in production of hippuric acid, and provides a method for producing hippuric acid, and the content of hippuric acid can reach 91.76 mg / L. The invention further provides a method for preparing the metagen from the complex microbial inoculant FGXOS and application of the complex microbial inoculant FGXOS or the prepared metagen in improvement or treatment of hyperuricemia, the hippuric acid content in the metagen prepared from the complex microbial inoculant FGXOS can reach 356.54 mg / kg, the hyperuricemia can be remarkably improved, and safety is high.

The invention discloses an animal model construction method for fetal osteoporosis, a prevention and treatment target and application of the prevention and treatment target. The fetal osteoporosis animal model is a filial generation rat which is obtained after a pregnant female Wistar rat is subjected to intragastric administration of Acimoline (300 mg / kg. D) in the pregnancy period. Weaning is conducted four weeks after birth, male and female are separated from cages and fed to 12 weeks, the peak bone mass of female offspring is remarkably reduced, and therefore the animal model with exposed Acimoline during pregnancy is established. On the basis of a pregnancy-stage Acimoline exposed rat model, 20 mg / kg hippuric acid is intragastric injected in the pregnancy stage, and peak bone mass reduction of female offspring can be effectively corrected. The animal model established by the invention is novel, reliable, simple and convenient, and application of hippuric acid in screening and preparing medicines for preventing and treating fetal osteoporosis is determined.

The present invention relates to a method of detecting a microorganism having hippuricase activity comprising contacting a sample to be tested with p-hydroxyhippuric acid or a salt thereof, a detection reagent and an oxidizing reagent. The present invention further relates to a kit comprising p-hydroxyhippuric acid, a detection reagent and an oxidizing reagent, and further relates to the use of the kit for detecting a microorganism having hippuricase activity or for discriminating a microorganism having hippuricase activity from a microorganism without hippuricase activity or to the use of the kit in a method of detecting a microorganism having hippuricase activity.

The invention discloses a method for preparing a rifimilast intermediate I by a chemical-enzyme method. According to the method disclosed by the invention, a compound II is taken as an initial raw material, a functional group ketonic acid is constructed by introducing hippuric acid, and a ketonic acid compound V is converted into a compound I under the catalytic action of transaminase. The route is simple to operate, does not need splitting, is high in atom economy and can be used for industrial production.

A metabolic marker combination and a detection kit thereof and the use thereof, a method for establishing a prediction model for an arteriosclerosis grade, and a method for evaluating an arteriosclerosis grade. The metabolic marker combination comprises: 2-hydroxybutyric acid, hydrogenated cinnamic acid, 2-phenylpropionic acid, methyl 5β-androstan-3β-ol-17β-carboxylate, C18:1 ceramide, vanilmandelic acid, menadione, piperine, hippuric acid, carnitine, propionyl glycine, myristic acid, urocanic acid, α-linolenic acid, and methionine and 5-hydroxymethyl-2-furoic acid. The efficient and accurate evaluation of the arteriosclerosis grade can be achieved.

A quinazoline derivative (represented by the formula (I)) salt's crystal form, a preparation method and application are provided; specifically, the hydrochloride crystal form A, B, C, D, F, H, I, Sulphate crystal form A, Maleate crystal form A, Succinate crystal form A, Adipate crystal form A, Glycolate crystal form A, Malate crystal form A, Fumarate Salt crystal form A, besylate crystal form A, B, C, benzoate crystal form A, hippurate crystal form A and oxalate crystal form A of the quinazoline derivative represented by formula (I). The salt crystal form provided by the present invention has good stability, which can be used in the treatment of non-small cell lung cancer brain metastasis, meningeal metastasis, primary brain cancer or glioma, etc., and has good bioavailability, which is of great significance for further research on the efficacy of such solid drugs.

A metabolic marker combination and a detection kit thereof and the use thereof, a method for establishing a prediction model for an arteriosclerosis grade, and a method for evaluating an arteriosclerosis grade. The metabolic marker combination comprises: 2-hydroxybutyric acid, hydrogenated cinnamic acid, 2-phenylpropionic acid, methyl 5β-androstan-3β-ol-17β-carboxylate, C18:1 ceramide, vanilmandelic acid, menadione, piperine, hippuric acid, carnitine, propionyl glycine, myristic acid, urocanic acid, α-linolenic acid, and methionine and 5-hydroxymethyl-2-furoic acid. The efficient and accurate evaluation of the arteriosclerosis grade can be achieved.

The present invention provides: a method for assessing the severity of premenstrual syndrome by using hippuric acid as an index; and a device therefor.　The present invention also provides: a method for assessing the severity of premenstrual syndrome of a subject by using hippuric acid in a sample derived from the subject as an index; a device for assessing the severity of premenstrual syndrome; and an assessment system for the severity of premenstrual syndrome.

The invention discloses a metabolic marker combination, a detection kit and application thereof, an establishment method of an arteriosclerosis level prediction model and an arteriosclerosis level evaluation method. The metabolic marker combination comprises 2-hydroxybutyric acid, hydrocinnamic acid, 2-phenylpropionic acid, 5 [beta]-androstane-3 [beta]-ol-17 [beta]-carboxylic acid methyl ester, C18: 1 ceramide, vanillic mandelic acid, menadione, piperine, hippuric acid, carnitine, propionyl glycine, myristic acid, urocanic acid, alpha-linolenic acid, methionine and 5-hydroxymethyl-2-furancarboxylic acid. The arteriosclerosis level evaluation can be efficiently and accurately carried out.

The present disclosure relates to various crystalline salts of (R)-2-(4-fluorophenyl)-2-(methylamino) cyclohex-1-one that are useful in the treatment of psychiatric disorders, including the treatment of mood disorders. These salts include their hydrochloride, sulfate, p-toluenesulfonate, mesylate, maleate, phosphate, tartrate, fumarate, citrate, glycolate, malate, and hippurate.

Methods of diagnosing Crohn's disease and ulcerative colitis in subjects is provided based on the determination of metabolites in urine samples, such as serine, hypoxanthine, kynurenine, threonine, indoxylsulfate, phenylacetylglutamine, 5-hydroxy-6-indolyl-O-sulfate, 5-(δ-carboxybutyl) homocysteine, sialic acid, guanidinosuccinic acid (GSA), glutamyl(iso) leucine, trigonelline, cresol sulfate, an anion having m / z: RMT: polarity of 345.1553:0.770: n, aminohippurate: GSA ratiometric biomarker, unknown anion (160.0615:0.830: n): tyrosine ratiometric biomarker and [GSA×Tyr]: [AHA×(an anion having m / z: RMT: polarity of 160.0615:0.830: n)] ratiometric biomarker.